We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Nextgen | LSE:NGG | London | Ordinary Share | GB00B7JRYW03 | ORD 50P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 78.00 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 78.00 | GBX |
Nextgen (NGG) Share Charts1 Year Nextgen Chart |
|
1 Month Nextgen Chart |
Intraday Nextgen Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 30/11/2012 | 12:53 | NextGen Group-AIM biotech minnow | 334 |
| 09/3/2012 | 07:11 | NextGen with Charts & News | 735 |
| 09/3/2012 | 07:09 | Positive news from NextGen | 1 |
| 19/2/2010 | 20:02 | Nextgen | 43 |
| 13/12/2009 | 14:26 | New Guinea Gold (TSX:NGG) | 57 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 02/10/2012 14:17 by the_doctor Hopefully not to many listened to the clueless rampers here like Stephanie MCrazy how much the managers were paying themselves in the run up to NGG going bust! The FSA should ban them from further roles for encouraging paid broker notes just before suspending and winding down the company Bad luck folk who invested I suspect the directors will now pick up the pieces for nothing with one of the major shareholders' backing instead? |
Posted at 08/5/2012 11:00 by bobby.ifa It was a dummy sale. I need these at £1.40 to break even Chesty, as I bought a load at a silly price pre-consolidation. |
Posted at 08/5/2012 10:18 by bobby.ifa New honcho appointed & buys in at £1.00. Price prior to news 70-75p. Seemes odd he would pay £1 for stock he could have got at a 30% discount in the market, therefore market speculates that he may know something. Also not much free stock about. When a sub penny share this would have massive volatility. |
Posted at 30/4/2012 17:03 by gammelgaard With a positive attitude one can get very far - thats my experience. And NGG is surely an interesting company, not to mention its products. Wait and see! |
Posted at 30/4/2012 15:09 by andrbea ngg 10%30/04/2012 15:06:15 NGG 0.20 O 2,600,000 30/04/2012 15:06:11 NGG 0.20 O 2,600,000 30/04/2012 12:12:38 NGG 0.15 O 1,700,000 30/04/2012 12:12:13 NGG 0.15 O 1,700,000 30/04/2012 11:10:07 NGG 0.14 O 275,000 |
Posted at 30/3/2012 15:46 by gobblehoof2 Hi BobbyTo respond to your question - NextGen's share price seems to have gone up on news that it is registering IP for its biomarkers which can diagnose and track the progress of early stage dementia. The news should be on the RNS section of this website if you want to have a look. |
Posted at 21/6/2011 07:47 by lady gaga .5p anyone lolHome Log In Register Our Services My Account Contact Help Stockwatch Level 2 Portfolio Charts Shares Magazine Research Share Price Indices Market Scan Company Zone Traders' Room NewsWatch Trades Terminal Alerts Stock Screener Heatmaps News iPhone Forex Director Deals Investors' Room Credit Cards A-Z of Brokers Directory Bookshop Awards 2011 Mortgages ISAs PLUS Simply Chart Broker Notes Forward Diary You are NOT currently logged in . Keyword Company EPIC/TIDM SEDOL/ISIN Tuesday 21 June, 2011 NextGen Group PLC New Assay Launch RNS Number : 7769I NextGen Group PLC 21 June 2011 NextGen Group Plc NextGen Sciences launches multiple protein cerebrospinal fluid (CSF) CNS disease biomarker assay London, UK and Ann Arbor, Michigan, US, 21 June 2011 - NextGen Group plc (AIM:NGG) is pleased to announce that its US-subsidiary NextGen Sciences Inc, a leader in biomarker discovery, measurement and qualification, has launched its first cerebrospinal fluid (CSF) multiple protein (multiplex) assay, csfdiscovery43, for central nervous system (CNS) biomarker discovery and qualification. The assay simultaneously measures 43 human CSF proteins that are thought to have potential as biomarkers in CNS diseases, particularly Alzheimer's, Parkinson's, multiple sclerosis and ALS diseases. The launch of csfdiscovery43 is the next step in NextGen Sciences strategy of becoming a leading player in the growing CNS and oncology biomarker markets. NextGen's assay is based upon its multiple reaction monitoring (MRM) mass spectrometry platform, and generates high quality reproducible data that companies can use in their drug and diagnostic development programmes. In addition to the CNS disease focus, the assay can be used for early-stage biomarker discovery and qualification in other disease areas e.g. traumatic brain injury (TBI). NextGen expects to continue to add proteins to the csfdiscovery43 assay, in addition to developing other disease-focused assay panels, both as proprietary products and with other companies through partnerships and collaborations. Klaus Rosenau, Chairman and CEO of NextGen Group, commented, 'The release of csfdiscovery43 is the next defining step in the development of NextGen Sciences' biomarker business, following its reorganization and release of the plasmadiscovery41 assay in Q1. It demonstrates that we have once again delivered on our plans to develop multiplex protein assays that will help to establish the company as a market leader in biomarker discovery and qualification using its MRM technology. Importantly, this enables us to further target increasing market share from the $600m mass spectrometry based biomarker discovery market. We believe that pharmaceutical, biotechnology and diagnostics companies need high-quality assays relevant to their disease areas to inform their decision-making processes, and NextGen Sciences is currently working on the launch of more such products.' - ENDS - For more information please contact : NextGen Group Klaus Rosenau, Chairman and CEO klaus.rosenau@nextge +49 160 551 6756 Seymour Pierce Jonathan Wright, Nicola Marrin +44 (0) 20 7107 8000 Notes to Editors NextGen Sciences Inc (Ann Arbor, MI, USA) is the subsidiary of NextGen Group PLC, London, UK (AIM: NGG). It provides pharmaceutical, biotechnology and diagnostic companies with rapid and quantitative protein biomarker discovery, measurement and qualification services using mass spectrometry technology. With a rise in the industry focus on personalized medicine and cost-effectiveness, biomarkers are playing an increasing important role in drug discovery, development and patient access, as well as healthcare delivery. The global market for biomarkers is expected to grow to $12.8bn by 2012 (BCC Research), with those for neurological disorders ($3.5bn by 2015, Espicom Healthcare) and oncology ($9.5bn by 2014, www.marketsandmarket This information is provided by RNS The company news service from the London Stock Exchange END MSCSESFMSFFSEFM Investegate takes no responsibility for the accuracy of the information within the site. The announcements are supplied by the denoted source. Queries about the content of an announcement should be directed to the source. Investegate reserves the right to publish a filtered set of announcements. NAV, EMM/EPT, Rule 8 and FRN Variable Rate Fix announcements are filitered from this site. -------------------- © 2011 Financial Express. All rights reserved. Stockwatch Level 2 Portfolio Charts Shares Magazine Research Share Price Indices Market Scan Company Zone Traders' Room NewsWatch Trades Terminal Alerts Stock Screener Heatmaps News iPhone Forex Director Deals Investors' Room Credit Cards A-Z of Brokers Directory Bookshop Awards 2011 Mortgages ISAs PLUS Simply Chart Broker Notes Forward Diary About an ADVFN competitor Ts and Cs Privacy Policy Investment Warning Content Standards Corporate Solutions Advertise With Us Site Map © 2011 an ADVFN competitor Register now for FREE Share Prices, Stock Quotes, Charts, Bulletin Boards, Indices, Watchlists, Portfolio, Market News, Research or see our Premium Services including Level 2, Terminal and much more. Follow us on Twitter |
Posted at 25/5/2011 11:05 by lady gaga Weve got a plug here.It looks like Tom likes us. The discovery that points to biotech's incredible revival... (This article first appeared in Penny Sleuth on 10 February 2011. Penny Sleuth is an unregulated free e-letter written by Tom Bulford and published by MoneyWeek Limited) 2010 was the year of the junior miner. Every week saw some plucky explorer score unbelievable gains. But this year is likely to be different, and I've got my eye on a few other sectors that I think could see fantastic successes in 2011. I've talked about food stocks and the remarkable recovery in UK manufacturing. But one sector that is really beginning to look exciting is biotech. Dormant for years and abandoned by investors as a non-starter, biotech looks to be on the cusp of a thrilling revival. After a string of dramatic announcements in recent months, it seems that investors have discovered a newfound enthusiasm for these stocks. Just look at what happened this week when drug researcher SAREUM HOLDINGS (SAR) revealed news of another exciting breakthrough... The discovery that points to Biotech's extraordinary revival On Monday Dr Tim Mitchell, Chief Executive of the Cambridge based drug researcher, reported that its Aurora+FLT3 Kinase programme had, in a pre-clinical in-vivo study, appeared to slow the progress of cancer. Ten leukaemia patients were treated with this compound and their 'leukaemia regressed to such an extent that no detectable cancer could be found in any of the cases treated'. By contrast for those who did not receive Sareum's compound their leukaemia 'increased five to fifteen fold'. That was enough to send Sareum's share price multiplying. Having drifted along for months at a price of about 0.25p, the shares took off, hitting 1.65p the following day and 4.79p on Wednesday. It has slipped back a little today. But those lucky enough to have been holding the shares and smart enough to have got out at the top could have multiplied their money nineteen-fold in the space of just three days. No less impressive was the extraordinary volume of shares that were traded. On Wednesday 1,142,362,883 Sareum shares were traded, representing over 80% of its entire issued capital, and the excitement spread elsewhere. Oxford-based PHYSIOMICS (PYC) has developed a simulation platform that can show how a tumour will react to drug exposure. It saw its share price surge from 0.25p to an intra-day high of 0.68p The US company NEXTGEN (NGG), which offers a suite of services that can increase the traditionally low success rates associated with biomarker development, flew from 0.11p to a high of 0.53p VALIRX (VAL), which focuses on the epigenomic analysis and treatment of cancer (the epigenome consists of chemical compounds that modify, or mark, the genome in a way that tells it what to do) almost doubled to 0.53p This is an extraordinary revival for a sector that has been languishing for so long that most investors have given it up. But you need to be very careful here... A sector shot through with risk - and scintillating rewards A cure for cancer is the equivalent of finding a river of liquid gold. But still, the biotech industry is fraught with danger. It eats up money, and genuine successes are few and far between. A few years ago high hopes were held for ANTISOMA (ASM), also a company looking for successful cancer drugs. This week it was described as a company 'that develops drugs that do not work'. That's a harsh but fair verdict on a company that has seen its share price sink from 36p to 2.2p over the last twelve months. Those who rushed into Sareum are already being brought face to face with some of the realities of biotech life. Today the company took advantage of the surge of interest to tap shareholders for £500,000, through the sale of 500m new shares at a penny a time. And a more careful reading of Sareum's Monday revelation shows that 'at six weeks following treatment, no detectable cancer could be found in two of the ten examples dosed with the Sareum compound. In the remaining eight treated examples, the average time taken for the leukaemia to increase five-fold was six weeks, compared to two weeks in the untreated cases'. So while Sareum's treatment seems to have some advantages over others, it appears to limit the spread of cancer, rather than kill it off completely. How marvellous it would be if Sareum had a cancer cure! But shareholders should prepare for a long and bumpy ride. Biotech research is a laborious process. While successful developments in this area often improve upon existing therapies, few provide a total cure. In time Sareum will need to find licensing partners, most probably big pharma companies with deep pockets. As big pharma cuts back on its own research spending, it is increasingly looking for small biotechs to do the early work, but the big boys do not move fast. |
Posted at 13/4/2011 10:50 by moochy I agree with your last comment doc. The thing with NGG's share price is that it increased by 600% in a matter of minutes not long ago, which brings out strong emotions in holders and this makes the share price prone to over reaction. Holders now "expect" a repeat of this kind of share price "ping" and as well because not too many shares are out there. I also agree with you in that fund raising is always a possibility. You can never foresee this. |
Posted at 19/3/2011 09:28 by loveabul What do people think of the late RNS friday.Is it good or bad news. Regulatory Story Go to market news section Company NextGen Group PLC TIDM NGG Headline Grant of Options Released 17:04 18-Mar-2011 Number 2618D17 RNS Number : 2618D NextGen Group PLC 18 March 2011 NextGen Group plc (the "Company") Grant of Options Ann Arbor, Michigan, US, and London, UK, 18 March 2011 - NextGen Group plc (AIM:NGG) is pleased to announce that on 18 March 2011 it approved an option plan totaling 2,584,014,751 options for management and employees of NGG and Next Gen Sciences Inc. (NGS) in the UK and the US. NextGen Sciences Inc., which is a subsidiary of NextGen Group, is a leader in biomarker discovery, measurement and qualification. The scheme has been created as an incentive stock option plan with clear near-term and long-term goals to be attained by management and employees for the options to vest, and represents an important part of the company's new biomarker business strategy. Approximately 30% of the total option plan (667,374,336 unissued shares currently authorized for allotment) vest pro rata to each option holder on 18 March 2011 and the remaining options will vest later and will be exercisable subject to satisfaction of objective criteria such as total profitability, sales and biomarker assay development. This remainder of the option plan will be issued and granted after approval at NGG'S AGM, expected to be held at the end of April this year. The options have an exercise price of 0.1p except for US employees where, for tax reasons, the exercise price has been set as the VWAP of shares in the Company for the 30 days prior to board approval, that is 0.33p., All options have to be exercised before 18 March 2021 whereafter they will lapse. The total option plan corresponds to 19.8% of the current fully diluted share capital. The total number of options held following this grant is set out below: Total holding as at 18 March 2011 Management and Board Klaus Rosenau, Chairman & CEO, NGG 273,685,139 Leif Hamø, CFO, NGG 117,293,631 Barry McAleer, CEO, NGS 117,293,631 Thomas Borcholte, non-executive director, NGG 10,500,000 Company Secretary Thomas Przygoda 15,000,000 Other employees UK employees 14,911,131 US employees 60,150,000 Other OAR GmbH1 33,715,804 Total 642,549,336 1 OAR GmbH is a German consultancy company that is doing consultancy work for NextGen Group. None of the above people or entities have options before this grant. Furthermore it has been agreed that NextGen Group Plc will pay its broker Dowgate Capital Stockbrokers Limited for services provided in 2010 and the first half of 2011 in shares in the Company, such shares to be issued at a price of 0.3p for 2,400,000 shares. Accordingly, application will be made for a total of 2,400,000 ordinary shares to be admitted to trading on AIM and trading is expected to commence on 24 March 2011. - ENDS - For more information please contact : NextGen Group Plc. Klaus Rosenau, Chairman and CEO klaus.rosenau@nextge +49 160 551 6756 Seymour Pierce Jonathan Wright, Nicola Marrin +44 (0) 20 7107 8000 Notes to Editors NextGen Sciences Inc. (Ann Arbor, MI, USA) is the subsidiary of NextGen Group Plc., London, UK (AIM: NGG). It provides pharmaceutical, biotechnology and diagnostic companies with rapid and quantitative protein biomarker discovery, measurement and qualification services using mass spectrometry technology. With a rise in the industry focus on personalised medicine and cost-effectiveness, biomarkers are playing an increasing important role in drug discovery, development and patient access, as well as healthcare delivery. The global market for biomarkers is expected to grow to $12.8bn by 2012 (BCC Research), with those for neurological disorders ($3.5bn by 2015, Espicom Healthcare) and oncology ($9.5bn by 2014, www.marketsandmarket This information is provided by RNS The company news service from the London Stock Exchange END RDSSFDFWAFFSESD London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply. ©2009 London Stock Exchange plc. All rights reserved Regulatory |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
